Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants

• Maxime Hentzien,
• Andrew Owen,
• Nathalie Strub-Wourgaft,
• Carmen Pérez-Casas,
• Marius Trøseid,
• Alexandra Calmy

Affiliations

Maxime Hentzien

HIV/AIDS Unit, Infectious Diseases Division, Geneva University Hospitals, Geneva, Switzerland

Andrew Owen

Centre of Excellence in Long-acting Therapeutics (CELT), University of Liverpool, Liverpool, United Kingdom

Nathalie Strub-Wourgaft

COVID Response and Pandemic Preparedness Director, Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland

Carmen Pérez-Casas

Strategy, Unitaid, Geneva, Switzerland

Marius Trøseid

Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital, Oslo, Norway

Alexandra Calmy

HIV/AIDS Unit, Infectious Diseases Division, Geneva University Hospitals, Geneva, Switzerland